No Detail Found!

Neurokinin 1 receptor antagonist along with dexamethasone reduces the inflammation in COVID-19 patients: a novel therapeutic approach

Author(s)
Riffat Mehboob Lahore Medical Research Center LLP and LMRC Laboratories,Lahore -,Pakistan; RotoGen Biotech Pvt. Ltd., Lahore - Pakistan
Fridoon Jawad Ahmad Department of Genetics, University of Health Sciences, Lahore - Pakistan
Ahad Qayyum Bahria International Hospital, Lahore - Pakistan
Muhammad Asim Rana Bahria International Hospital, Lahore - Pakistan
Muhammad Akram Tariq Higher Education Department (HED), Punjab, Lahore - Pakistan
Shadi Tamur Department of Pediatrics, College of Medicine, Taif University, Taif - Saudi Arabia
Imran Shahid Department of Pharmacology and Toxicology, Faculty of Medicine, Umm Al- Qura University, Al-Abidiyah, P.O.Box 13578, Makkah - Saudi Arabia
Iman M Mirza Public Health and Community Medicine, Family and Community Medicine Department, Faculty of Medicine, University of Tabuk, Tabuk - Saudi Arabi
Amany Fathaddin Pathology Department, College of Medicine, King Saud University, Riyadh - Saudi Arabia
Samy A Abusikkien Department of Anatomy, Faculty of Medicine, King Abdulaziz University, Rabigh, Saudi Arabia/Department of Anatomy, Ain Shams University, Cairo - Egypt
Mohamed A Zayed Department of Physiology, Faculty of Medicine, King Abdulaziz University, Rabigh - Saudi Arabia/ Department of Medical Physiology, Faculty of Medicine, Menoufia University - Egypt
Abstract
Background: Corona virus infection is a respiratory infection, compromising the normal breathing in critical patients by damaging the lungs. The aim of this study was to evaluate the clinical outcomes of Substance P receptor Neurokinin 1 antagonist in COVID-19 patients against the usual treatments as controls. Methods: It is a two-arm, open-label, randomized clinical trial that was carried out at Bahria International Hospital in Lahore, Pakistan. PCR-positive, hospitalized patients older than 18 years old, all sexes, and in the critical to life-threatening stage were included. 52 patients were placed in control group A and 67 patients were placed in intervention group B out of a total 119 patients who were randomly assigned to both arms. Before and after the intervention, lab tests were conducted in both groups. Aprepitant, a neurokinin-1 receptor antagonist, was additionally administered to the other arm while the other arm got standard therapy and care. Additionally, both groups received oral administration of the corticosteroid dexamethasone. Results: Patients in group A were on average 56.05 years old, compared to 58.1 years old in group B. There were 24 women in group A and 28 in group B, while there were 28 men and 39 women in group A. Group A had three critical cases, but group B had six. The reduction in C-reactive protein in the intervention group, improvement in platelet count in group B, and normalization of ferritin and LDH levels in group B all indicated decreased inflammation in the biochemical and haematological parameters in both groups. However, because of the reduced sample size, it wasn't very significant. Conclusion: The results of this recent trial provide a solid indication of Aprepitant's medicinal potential. Patients who got a combined therapy of dexamethasone and aprepitant had better clinical results, more favourable lab results, and lower levels of C-reactive protein, an inflammatory marker.
Publication Details
Page(s) 426-433
DOI DOI not available
Published Journal: Advancements in life sciences, Volume: 10, Issue: 3, Year: 2023

Request the full text from PASTIC

Keywords
COVID-19 Infection, Dexamethasone, treatment, Aprepitant, Neurokinin-1 receptor, Trigeminal nerve, Substance p
0

Citations

0

Downloads

45

Views